TARA
Protara Therapeutics Inc
NASDAQ: TARA · HEALTHCARE · BIOTECHNOLOGY
$2.49
+0.81% today
Updated 2026-10-28
Market cap
$138.87M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.37
Dividend yield
—
52W range
$2 – $8
Volume
1.1M
WallStSmart proprietary scores
32
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C8.0
Quality
A3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
7.0
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →270 stocks currently score above 75
Price targets
Analyst target
$25.71
+932.53%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 6.95 — safe zone
+ Debt/equity 0.02x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-15.72M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-65.95M | $-40.42M | $-44.60M | $-57.44M | $-21.67M |
| EPS | — | — | — | — | $-1.37 |
| Free cash flow | $-26.58M | $-37.60M | $-35.87M | $-56.46M | $-15.72M |
| Profit margin | — | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-08 | ZUMMO, JACQUELINE | Sale | 1,134 | $5.40 |
| 2026-04-01 | ZUMMO, JACQUELINE | Sale | 22,598 | $5.26 |
| 2026-01-26 | ZUMMO, JACQUELINE | Sale | 3,724 | $6.67 |
Peer comparison
Smart narrative
Protara Therapeutics Inc trades at $2.49. Our Smart Value Score of 32/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of 6.95, it sits in the safe zone.
Frequently asked questions
What is Protara Therapeutics Inc's stock price?
Protara Therapeutics Inc (TARA) trades at $2.49.
Is Protara Therapeutics Inc overvalued?
Protara Therapeutics Inc carries a Smart Value Score of 32/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Protara Therapeutics Inc (TARA)?
The 12-month analyst consensus target is $25.71, about 932.5% above the current $2.49. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Protara Therapeutics Inc's Altman Z-Score is 6.95, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-47.85%
Beta1.47
50D MA$3.31
200D MA$4.62
Shares out0.06B
Float0.05B
Short ratio—
Avg volume1.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—